SUSTOL represents the latest formulation of injectable, single-agent 5-HT3 RAs1-5

Timeline of 5-HT3 RAs leading to SUSTOL

SUSTOL protects your patients during both the acute and delayed phases

  • SUSTOL is the first and only extended-release 5-HT3 RA that utilizes polymer technology1-3,6-8
  • Palonosetron is not indicated for prevention of delayed CINV associated with HEC1

Why choosing the right 5-HT3 RA is important

Consequences of uncontrolled CINV to consider:

  • Delays or discontinuation of future chemotherapy cycles9,10
  • Impact on quality of life by increasing the potential for hospitalizations and unscheduled visits for hydration11,12
  • Risk for medical complications such as malnutrition, weight loss, and electrolyte imbalances11,12
  • Additional treatment, including reliance on rescue medications11

Earlier 5-HT3 RA formulations with a shorter duration of action may not protect patients from both acute and delayed CINV1-3

5-HT3 RA=5-hydroxytryptamine receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy.

References:

  1. Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., 2020.
  2. Zofran [prescribing information]. GlaxoSmithKline. 2017.
  3. Kytril [prescribing information]. Genentech, Inc., 2011.
  4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Anzemet injection approval letter. October 11, 1997.
  5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. SUSTOL injection approval letter. August 9, 2016.
  6. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.
  7. Sancuso [prescribing information]. Kyowa Kirin, Inc., 2020.
  8. Anzemet [prescribing information]. Validus Pharmaceuticals LLC, 2016.
  9. Van Laar et al. Support Care Cancer. 2015.
  10. Neymark et al. Support Care Cancer. 2005.
  11. Hawkins et al. Clin J Oncol Nurs. 2009.
  12. Burke et al. Support Care Cancer. 2011.
  13. Gabrail et al. Cancer Manag Res. 2015.
  14. Data on File [C2006-01]. Heron Therapeutics, Inc.